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medical therapies were randomized to receive either the EX-PRESS or a trabeculec-
tomy. Clinical outcomes included intraocular pressure (IOP), use of IOP lowering
medications and post-operative eye surgeries. The study follow-up was 5 years.
The economic perspective was the one of the French society. EX-PRESS cost was
not included. Patients were considered a success if they had an IOP less than or
equal to the success thresholds of 15 or 18 mmHg, without IOP lowering medica-
tions, and without having undergone further glaucoma surgery. Time to failure
was analyzed using a log rank test. Costs were discounted at a 3% rate. RESULTS: 78
patients were analyzed, 39 in each arm. EX-PRESS eyes had better IOP control at 1
(12.0 vs 13.9 mmHg; P0.02), 2 (11.9 vs 13.8 mmHg; P0.01) and 3 years (12.0 vs 13.5
mmHg; P0.04). The five-year failure rate was 41% for EX-PRESS versus 69% for
trabeculectomy (P0.005) using an 18 mmHg IOP target and 46% versus 77%
(P0.001) for 15 mmHg. At year 5, 41.0% of the EX-PRESS patients had an IOP
lowering drug prescription versus 53.9% for the trabeculectomy patients. EX-PRESS
patients received 0.85 IOP lowering medications versus 1.10 in the trabeculectomy
group. EX-PRESS patients required less needling (2 versus 5) and had fewer cataract
surgeries (5 versus 8). Without discounting, drug savings with EX-PRESS equaled
€277.00, €331.02 as a total. With a 3% discounting, the figures became €260.00 and
€342.97, respectively. CONCLUSIONS: At 5 years after surgery, EX-PRESS demon-
strated that it better controls IOP than trabeculectomy, resulting in post-operative
savings.
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OBJECTIVES: ST2 is a blood test that accurately risk stratifies patients with heart
failure (HF). This enables physicians to select high risk patients for intensive dis-
ease management (DM) programs. We evaluated the cost-effectiveness of ST2 in
patients discharged from hospital after an acute heart failure event.METHODS:We
developed a decision-analytic model to explore the 30-day mortality and cost out-
comes. A horizon of 30 days was used as a recognized hospital quality metric. We
compared two clinical scenarios: 1) HF patients did not enter DM programs; 2) only
patients with ST235 ng/ml entered DM programs. The clinical data came from the
Basel study, a prospective, blinded study of 591 HF subjects. We modeled the mor-
tality, the hypothetical reimbursement of ST2 testing, costs of DM and hospitaliza-
tions. A US health care system perspective was taken. A range of sensitivity anal-
yses and scenario analyses were performed. RESULTS: We simulated a cohort of
patients with a mean age of 78 years old over the 30-day period post discharge.
During that period there was 11.8% mortality and 20.1% all cause re-hospitalization
rates. We assumed a 26% reduction in mortality and a 21% reduction in re-hospi-
talization from intensive DM based on a peer-reviewed meta-analysis. The base
case showed that the ST2 strategy reduces lost life years by 0.217 with cost saving
of $1079 per tested patient when compared to no DM. Sensitivity analyses suggest
that the model is most sensitive to the cost of re-hospitalization and the cost and
effectiveness of the intensive DM program. CONCLUSIONS: Under a variety of
scenarios, prediction of 30-day HF risk with ST2, in order to select high risk patients
for enrollment into intensive DM programs, reduces mortality and is cost saving.
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COST EFFECTIVENESS ANALYSIS OF INTRATHECAL BACLOFEN THERAPY (
TRICUMED™) VERSUS MEDICAL TREATMENTS FOR SEVERE SPASTICITY IN
TURKEY
Malhan S1, Oksuz E2, Ozsezer Y3
1Baskent University, Ankara, Turkey, 2Baskent University, Ankara, Turkey, 3Neuromodulation
Group, Ýstanbul, Turkey
OBJECTIVES: The objective was from a Turkish perspective to analyse the incre-
mental cost-effectiveness of Intrathecal baclofen therapy ( Tricumed™) compared
with medical treatment in adults for severe spasticity in Turkey. METHODS: We
compared the costs and health effects of intrathecal baclofen therapy with stan-
dard treatment only, from the health care perspective for a 1-year period. Health
effects were expressed in terms of an “ashworth score” as a year. The ashworth
score data was collected from the literature for both Intrathecal Baclofen Therapy
and medical treatment for severe spasticity. The cost of the treatments were cal-
culated based on the treatment guidelines for Turkish patient from the Turkish
health care payer’s perspectives. RESULTS: The annual average cost of Intrathecal
Baclofen Therapy per patient has been estimated to be €10357,27. On the other
hand, the yearly average cost of medical treatment per patient has been found as
€6080,16. The incremental cost effectiveness ratio (ICER) for Intrathecal Baclofen
Therapy versus Medical Treatment for severe spasticity analysed as 89,33€ per
“ashworth score”. CONCLUSIONS: Intrathecal Baclofen Therapy is a cost-effective
technology for the severe spasticity patients compared to the medical treatment
for severe spasticity in Turkey.
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OBJECTIVES: The FAME Study is an international multicenter randomized clinical
trial (n1,005), which demonstrated a significant improvement in health outcomes
for patients with multivessel coronary artery disease undergoing percutaneous
coronary intervention (PCI) guided by fractional flow reserve measurement (FFR)
compared to PCI guided by angiography alone. We performed a cost-effectiveness
analysis along the FAME trial to estimate the cost effectiveness of FFR in France and
Belgium and compared the results with those of other European countries.
METHODS: We used original patient-level data of the FAME study (Tonino et al.,
NEJM 2009) to estimate resource consumption, which was valued using prices from
French and Belgian price lists and DRG catalogues (2010 values). Utilities were
measured with EQ-5D based on French time trade-off and Torrance-transformed
Belgian visual analogue scale (VAS) weights. We adopted a societal perspective and
a one-year time horizon (i.e., follow-up of the FAME Study). Variability was exam-
ined using one-way sensitivity analysis and bootstrap resampling (n5000). Re-
sults are expressed in incremental costs (EUR) and incremental QALYs. RESULTS:
In both countries, FFR slightly improved QALYs (p0.05) at significantly lower costs
(p0.05). Cost savings reached approximately 900 EUR/patient for both countries.
For both countries, bootstrap analysis showed that FFR was cost saving in50% of
all bootstrap samples and cost effective in 90% when using a cost-effectiveness
threshold of 50,000 EUR/QALY. The most influential cost components were prices
for DES and FFR pressure wires. Cost-savings in France and Belgium are higher than
recently presented results for Germany, the UK and Italy, where FFR is cost saving
with savings ranging from 300-600 EUR/patient. CONCLUSIONS: In the context of
the health care systems of Belgium and France, FFR-guided PCI is cost saving (dom-
inant) in patients with multivessel coronary artery disease. These results are ro-
bust and in line with those of other European countries.
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OBJECTIVES: An ongoing 2-year local prospective study to compare clinical, hu-
manistic and economic outcomes of Drug Eluting Stents (DES) and Bare Metal
Stents (BMS). METHODS: All patients receiving DES or BMS placement in Prince of
Wales Hospital in Hong Kong within the period of September 2009 to March 2010
were recruited and followed for 12 months. Clinical outcome was measured by
occurrence of major adverse cardiac events (MACE). EQ-5D questionnaire, with
visual analog scale (VAS), was used to assess patients’ health-related quality of life.
The questionnaire was administered by patients before procedure, at 6 month and
12 month. Cost of index procedure and follow-up were recorded and cost per QALY
of DES over BMS was used to evaluate cost-effectiveness of DES. Subgroup analysis
was performed on patients with diabetes mellitus (DM). RESULTS: 325 patients
were enrolled (n210 for DES and n115 for BMS), with balanced baseline charac-
teristics. MACE was significantly less common in DES group (n10, 4.8% vs n14,
12.2%; OR0.361, 95% Cl0.155 to 0.841). The increase in utility score at 12 month
was 0.22 for DES group and 0.17 for BMS group (p0.294). Aggregate 12-month cost
was higher in DES group (HK$110,640 68,706 vs HK$99,802 93,420; p0.235). Cost per
QALY gained for DES was HK$184,564. Subgroup analysis showed that cost per
QALY was HK$15,303 in DM patients. Subsidizing DM patients to use DES, instead
of BMS, could save up to HK$6,370,000 annually for Hospital Authority. (1US$ 7.8
HK$) CONCLUSIONS: DES was shown to be superior to BMS in clinical outcome.
Even with higher procedural cost in DES group, the lower follow-up cost resulted in
gradually smaller difference in aggregate cost. DES was more cost-effective than
BMS, especially in DM patients. Subsidizing DM patients to use DES would be cost-
saving and lead to better clinical outcome.
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OBJECTIVES: Neutropaenia, a chemotherapy-related adverse event, is graded in
terms of severity and can have different relative effects on health and resource use.
For advanced colorectal cancer (CRC) patients on irinotecan-based chemotherapy,
UGT1A1 testing can stratify populations into different risk groups to potentially
reduce the incidence of febrile neutropaenia, which may also impact on healthcare
resources. High-risk patients can be prescribed lower irinotecan doses to reduce
febrile neutropaenia. Two previous economic evaluations of UGT1A1 testing fo-
cussed on reducing grade 3&4 neutropaenia. This study aimed to assess the cost-
effectiveness of UGT1A1 testing to reduce the incidence of irinotecan-related fe-
brile neutropaenia. METHODS: An economic model of UGT1A1 testing to predict
febrile neutropaenia compared to standard care was developed over a lifetime
horizon from the UK NHS perspective. Treatment pathways were informed by a
national survey of CRC experts (n44). Model inputs were identified from: a micro-
costing observational study (n48 patients), CRC expert (n55) elicitation and pub-
lished literature. RESULTS: UGT1A1 testing was cost-saving and resulted in lower
incidence of febrile neutropaenia. For a cohort of 100 patients, the test was esti-
mated to save £17,700, avoid 0.4 febrile neutropaenic episodes, gain 0.006 life-years
and 0.007 QALYs. The likelihood that the test was cost-effective was 94% at a
threshold of £25,000 per QALY gained. Sensitivity analysis (probabilistic and one-
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way) suggested the largest driver of cost-effectiveness was the effect of irinotecan
dose reduction on survival. Value of information analysis indicated a low value of
future research to reduce parameter uncertainty (5 year population EVPI: £31,564).
However, assumptions affecting model structure had a relatively higher impact on
cost-effectiveness.CONCLUSIONS:This is the first economic evaluation of UGT1A1
testing to reduce the incidence of febrile neutropaenia. This study illustrated the
importance of considering febrile neutropaenia in addition to grade 3 and 4 neu-
tropaenia in evaluations of UGT1A1 testing.
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OBJECTIVES: Rituximab (Rmb), Imatinib (Imt) and extra-corporeal photopheresis
(ECP) are some of the strategies used as rescue therapy among patients with
chronic graft-versus-host disease (cGVHD) who failes previous lines of treatment.
The purpose of the study was to assess the cost-effectiveness of ECP in patients
with cGVHD in Spain. METHODS: A Microsimulation model was built to estimate
the clinical and economic consequences of ECP versus Rmb or Imt for 1000 hypo-
thetical patients. Model probabilities concerning the efficacy of ECP, Rtm and Imt
and severity degree per organ affected were obtained from literature. Treatment
pathways and adverse events were evaluated taking into consideration expert
opinion. Local data on costs (Euros 2010) and use of health resources were also
validated by clinical experts. An annual 3% discount rate was applied to costs and
outcomes. The perspective was the Spanish National Health System and time ho-
rizon was 5 years. RESULTS:Differences in improvement when ECP is used showed
a gain at first year of 6.2% and of 6.7% against Rmb and Imt, respectively. The higher
efficacy of ECP leads to a gain of 0.011–0.024 Quality Adjusted Life Year in the first
year and 0.062-0.094 at year five compared to Rmb or Imt. Results showed than
higher acquisition cost of ECP vs Imt was compensated at 9 months by higher
efficacy and vs Rmb was partially compensated (517€ year 5). After 9 months, ECP
was dominant vs Imt. The incremental cost-effectiveness ratio of ECP versus Rmb
was 29,646€ per LY gained and 24,442 € per QALY gained at year 2.5. The probabi-
listic sensitivity analysis show robustness of results, being the ECP cost-effective in
70% of the simulated cases at year 5 (threshold of €30,000 per QALY gained).
CONCLUSIONS: ECP as third-line therapy for cGVHD is a more cost-effective com-
pared to Rmb or Imt.
PMD44
ECONOMIC EVALUATION OF THE UGT1A1 PHARMACOGENETIC TEST TO
INFORM DOSE SELECTION OF IRINOTECAN-BASED CHEMOTHERAPY
Shabaruddin FH1, Elliott RA2, Tappenden P3, Payne K4
1University of Malaya, Kuala Lumpur, Malaysia, 2University of Nottingham, Nottingham, UK,
3University of Sheffield, Sheffield, UK, 4University of Manchester, Manchester, UK
OBJECTIVES: The UGT1A1 pharmacogenetic test can potentially inform irinotecan
dose selection and reduce the incidence of neutropaenia, a key adverse event of
irinotecan-based chemotherapy in advanced colorectal cancer (CRC). Neutropae-
nia has a negative impact on health and its management uses healthcare re-
sources. The UGT1A1 test identifies patients at low-, intermediate- or high-risk of
grade 3&4 neutropaenia. High-risk patients can be prescribed lower doses to reduce
the incidence of neutropaenia. This study aimed to assess the cost-effectiveness of
UGT1A1 testing and identify key parameters driving cost-effectiveness.METHODS:
An economic model of UGT1A1 testing to predict grade 3&4 neutropaenia com-
pared to standard care was developed over a lifetime horizon from the UK NHS
perspective. Treatment pathways were informed by a national survey of CRC ex-
perts (n44). The model was populated with data from: systematic reviews of the
effectiveness and utility literature; a micro-costing observational study (n48 pa-
tients) and CRC expert (n55) elicitation. RESULTS: UGT1A1 testing was cost-sav-
ing and resulted in lower incidence of grade 3&4 neutropaenia. For a cohort of 100
patients, the test was estimated to save £14,500, avoid 4.4 neutropaenic episodes,
gain 0.06 life-years and 0.05 QALYs. The probability that the test was cost-effective
at willingness-to-pay thresholds between £20,000 and £30,000 per QALY gained
was above 95%. These findings were specific to model assumptions and specifica-
tions. Sensitivity analysis (probabilistic and one-way) suggested that the main
driver of cost-effectiveness was the effect of irinotecan dose reduction on survival.
Value of information analysis indicated a low value of future research to reduce
parameter uncertainty (5 year population EVPI: £13,116). In contrast, assumptions
affecting model structure had a comparatively greater impact on
cost-effectiveness. CONCLUSIONS: This analysis modelled NHS-relevant clinical
treatment pathways and provided potentially useful evidence for UK decision-
makers. Structural model assumptions rather than parameter inputs had a larger
impact on cost-effectiveness.
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OBJECTIVES: Aortic valve stenosis is a chronic and progressive valvular heart dis-
ease. The standard treatment of this condition involves a major open surgery. For
patients currently ineligible for surgery, medical management is the only option
available. Transcatheter aortic valve implantation (TAVI) devices recently ap-
peared as a new less invasive treatment option. The objective of this study was to
develop an exploratory cost-effectiveness analysis of TAVI vs Optimal Medical
Treatment (OMT) in the Portuguese Setting. METHODS: This analysis used a
Markov model developed by Oxford Outcomes to assess costs and benefits of TAVI
vs OMT. A short term sub-model represents the first 30 days after TAVI (cycle
length of one day), whereas a long term model (cycle length of one month) consid-
ers a 10-year time horizon. For TAVI patients the health states considered are ICU,
General Wards, Home, Re-operation and Death. OMT patients are in either Home or
Dead health states, receiving medication until death and at risk of co-morbidity-
related hospitalisations. Portuguese NHS healthcare resource consumption was
retrospectively collected at Hospital de Santa Cruz in Lisbon for a cohort of 44 high
risk AS patients (21 TAVI; 23 OMT), over a period of 11 months. Clinical parameters,
transition probabilities and utility values were derived from relevant literature.
Costs were taken from the official Portuguese published tables and hospital re-
ports. Costs and benefits were discounted at 5% p.a. Probabilistic and one-way
sensitivity analysis were performed. RESULTS: Treatment with TAVI compared to
OMT increased life years by 1.7 (3.13 vs. 1.46) and quality-adjusted life years
(QALYs) by 1.4 (2.23 vs. 0.80). Direct costs were 32,067€ with TAVI and 4,662€ with
OMT. Incremental Cost Effectiveness Ratios (ICERs) estimated are 16,375 € /LYG and
19,180 € /QALY. CONCLUSIONS: TAVI is highly likely to be a cost-effective inter-
vention for the treatment of AS in patients who are currently ineligible for surgery.
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OBJECTIVES: In Hungary the re-regulated, transparent coverage system of medical
aids was put into force in 2007 (after the re-regulation of coverage policy of drugs
/2004/). Until 2010 287 reimbursement applications were evaluated by the Office of
HTA of the National Institute for Strategic Health Research. The aim of the study
was to develop a standard reimbursement dossier, which evidenced the effective-
ness and cost-effectiveness of a new medical device (Nebulizer Mini-Plus).
METHODS:According to a recommendation of the above mentioned HTA Office the
combined assessment of technical functions and prices was suggested as eligible
filter for the coverage of products with sufficient price-value rate. Hence the base of
the study was: to compare the technical parameters of nebulizers and to use the
cost-minimization analysis (CM). The study had payer’s perspective, but aspect of
equity (burden of disease) was taken into consideration because of the high signif-
icance of diseases of respiratory system. After the literature review and compari-
son of technical parameters of nebulizers, the 2009-2010 turnover of nebulizers
were analysed and the budget impact was estimated for 2011-2012, considering the
business risks. RESULTS: Taking into consideration that several technical param-
eters (lung deposition, particle size) of Mini-Plus exceeded other devices and its
price was lower than the cheapest reimbursed device: it was expressed as the
dominant alternative of compression nebulizer therapies. By its coverage the payer
can reach almost 15.000 USD saving and minimally 3685 USD burden loss (reducing
of co-payment) for patients until 2012. There are additionally cost-saving poten-
tials in reduction of drug consumption and hospitalization. CONCLUSIONS: The
combined assessment of technical functions and prices (supported by CM) was a
successful and eligible strategy for the evaluation of the effectiveness and cost-
effectiveness of a new medical device, and can be adapted for other types of med-
ical aids.
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OBJECTIVES: End-stage heart failure is a leading cause of death; patients have a
poor prognosis and low quality of life. Managing the limiting and distressing symp-
toms places significant costs on the NHS. Therapy options are few; primarily com-
bination medical therapy and, for a few patients, transplantation using a donor
heart. Left ventricular assist devices (LVADs) are mechanical pumps that support
the heart function. Use is increasing worldwide as more studies demonstrate clin-
ical effectiveness, primarily from improved patient survival and quality of life.
However, there are no published cost effectiveness studies. This pilot evaluates the
cost effectiveness of the HeartWare LVAD as destination therapy for patients with
end-stage heart failure. METHODS: A cost-utility model compared the outcomes
and costs of patients who were medically managed without a transplant (n15)
with those who received a HeartWare LVAD and no subsequent transplant (n17).
Clinical data were from a multicentre trial evaluating the safety and efficacy of the
HeartWare LVAD [1] and outcomes for patients listed on the NHS Blood and Trans-
plant Registry [2]. Utility values were from a Health Technology Assessment [3] and
derived using the EQ-5D tool. Cost data came mainly from published sources.
RESULTS: The results from this evaluation were patients managed with the Heart-
Ware device had higher costs but better outcomes than those who were medically
managed. At 5 years the additional cost was about £20,500 per patient and a QALY
gain of 1.05, giving an incremental cost per QALY of under £20,000, below the
threshold commonly adopted of £25,000 per QALY. CONCLUSIONS: The results are
encouraging and suggest it is plausible that using LVADs as long-term support in
patients with end-stage heart failure could be a cost-effective use of healthcare
provider resources. Further research is needed to refine the clinical and cost data.
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